84 related articles for article (PubMed ID: 18691250)
1. Alleviation of myelodysplastic syndrome-associated skin rush after treatment with decitabine.
Papaioannou M; Sapalidis K; Kotoula V
Eur J Haematol; 2008 Dec; 81(6):489-90. PubMed ID: 18691250
[No Abstract] [Full Text] [Related]
2. Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine.
Kim J; Kim YR; Lee KA
Leuk Lymphoma; 2012 Nov; 53(11):2287-9. PubMed ID: 22468921
[No Abstract] [Full Text] [Related]
3. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
Almeida AM; Pierdomenico F
Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
[No Abstract] [Full Text] [Related]
4. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
5. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.
Haas PS; Wijermans P; Verhoef G; Lübbert M
Leuk Res; 2006 Mar; 30(3):338-42. PubMed ID: 16162357
[TBL] [Abstract][Full Text] [Related]
6. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
7. Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
Cashen AF; Devine H; DiPersio J
Am J Hematol; 2006 Jul; 81(7):543-5. PubMed ID: 16755561
[TBL] [Abstract][Full Text] [Related]
8. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
9. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
Liu Y; Tabarroki A; Billings S; Visconte V; Rogers HJ; Hasrouni E; Englehaupt R; Kalaycio M; Sekeres MA; Saunthararajah Y; Tiu RV
Leuk Lymphoma; 2014 Feb; 55(2):447-9. PubMed ID: 23647061
[No Abstract] [Full Text] [Related]
10. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
11. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
12. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
13. [Autoimmune hemolytic anemia and myelodysplastic syndrome].
Javier G; Juncá J; Millá F; Prats J
Sangre (Barc); 1990 Dec; 35(6):488. PubMed ID: 2087670
[No Abstract] [Full Text] [Related]
14. Sustained trilineage hematopoietic recovery in a patient with refractory anemia, del(13)(q12q22), and paroxysmal nocturnal hemoglobinuria-type cells treated with immunosuppressive therapy.
Kasahara I; Nishio M; Endo T; Fujimoto K; Koike T; Sugimori N; Katagiri T; Nakao S
Leuk Res; 2011 Sep; 35(9):e147-8. PubMed ID: 21641038
[No Abstract] [Full Text] [Related]
15. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G
Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938
[TBL] [Abstract][Full Text] [Related]
16. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
Shao XR; Liang H; Guan XJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
[No Abstract] [Full Text] [Related]
17. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Ziarkiewicz M; Dwilewicz-Trojaczek J; Pastwińska A; Chmarzyńska E; Paszkowska-Kowalewska M; Koperski Ł; Jędrzejczak WW; Ziarkiewicz-Wróblewska B
Pol J Pathol; 2010; 61(2):105-9. PubMed ID: 20924996
[TBL] [Abstract][Full Text] [Related]
18. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
Choi SH; Byun HM; Kwan JM; Issa JP; Yang AS
Br J Haematol; 2007 Sep; 138(5):616-23. PubMed ID: 17686055
[TBL] [Abstract][Full Text] [Related]
19. [Autoimmune hemolytic anemia in a myelodysplastic syndrome].
Perdiguer L; Bergua J; Marzo L; Delgado P; Rubio Félix D
Sangre (Barc); 1990 Aug; 35(4):330. PubMed ID: 2274844
[No Abstract] [Full Text] [Related]
20. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Itzykson R; Thépot S; Beyne-Rauzy O; Ame S; Isnard F; Dreyfus F; Salanoubat C; Taksin AL; Chelgoum Y; Berthon C; Malfuson JV; Legros L; Vey N; Turlure P; Gardin C; Boehrer S; Ades L; Fenaux P;
Leuk Res; 2012 Apr; 36(4):397-400. PubMed ID: 22177456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
